15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
11:00 , Nov 15, 2018 |  BC Extra  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and cell culture studies identified two thiazolidinedione-based dual inhibitors of tau-aggregation and GSK3B that could help treat AD. Chemical synthesis and in vitro testing in enzymatic activity assays of...
19:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Janssen's esketamine meets in Phase III to prevent treatment-resistant depression relapse

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said intranasal esketamine (formerly JNJ-54135419) plus an oral antidepressant met the primary endpoint of delaying time to relapse during maintenance treatment compared with an oral...
19:23 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Janssen reports long-term safety data for esketamine in treatment-resistant depression

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported data from the Phase III SUSTAIN-2 long-term safety study evaluating intranasal esketamine (formerly JNJ-54135419) plus an oral antidepressant to treat treatment-resistant depression showing there...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
04:46 , Jun 21, 2018 |  BC Extra  |  Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
18:33 , May 25, 2018 |  BC Week In Review  |  Financial News

Aptinyx proposes $80M IPO

Neurology company Aptinyx Inc. (Evanston, Ill.) proposed to raise $80 million on May 23 in an IPO on NASDAQ underwritten by J.P. Morgan, Cowen, Leerink and BMO Capital Markets. The company expects data in 1H19...
23:14 , May 23, 2018 |  BC Extra  |  Financial News

Aptinyx proposes $80M IPO

Neurology company Aptinyx Inc. (Evanston, Ill.) proposed to raise $80 million in an IPO on NASDAQ underwritten by J.P. Morgan, Cowen, Leerink and BMO Capital Markets. The company expects data in 1H19 from a pair...
17:27 , May 11, 2018 |  BC Week In Review  |  Clinical News

J&J reports mixed Phase III data of esketamine for depression

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported mixed data from two double-blind, international Phase III trials evaluating intranasal esketamine (formerly JNJ-54135419) to treat treatment-resistant depression. The NMDA receptor antagonist met the...